Ignyta Announces Two Entrectinib Phase I Data Presentations and Webcast Management Presentation at the 2015 ASCO Annual Meeting

Ignyta, Inc.

, a precision oncology biotechnology company, today announced the publication of two abstracts for the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). Both abstracts were accepted for poster presentations, with one of the abstracts also being selected for a poster discussion session. Both of the poster presentations relate to the results of Phase I clinical trials of entrectinib, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to TrkA, TrkB, TrkC, ROS1 or ALK, and will be held on May 30, 2015, in Chicago, Illinois. "We are honored that the ASCO Scientific Program Committee has selected the abstracts describing exciting data from our two Phase I clinical trials of entrectinib for poster presentations and a poster discussion session," said Pratik Multani, M.D., Chief Medical Officer of Ignyta. "We are looking forward to sharing updated data from these clinical trials in this prestigious scientific forum, and to discussing the data and our future clinical development plans for entrectinib with key scientific and clinical experts during the ASCO meeting." Details of the presentations are as follows: Title: ALKA-372-001: First-in-human, Phase I study of entrectinib – an oral pan-Trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. (Abstract number 2517, Poster number 233) Date/time: Saturday, May 30, 2015, 8:00 AM – 11:30 AM, Central time (Poster Presentation) Saturday, May 30, 2015, 1:15 PM – 2:30 PM, Central time (Poster Discussion Session) Title: STARTRK-1: Phase 1/2a study of entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. (Abstract number 2596, Poster number 312) Date/time: Saturday, May 30, 2015, 8:00 AM – 11:30 AM, Central time (Poster Presentation) In addition, Ignyta announced that it will host a reception in Chicago, Illinois, on Sunday, May 31, 2015, at which its management team will make a presentation relating to the entrectinib Phase I data, the company's plans for further development of entrectinib and other company highlights. The presentation will take place at 6:30 PM, Central time. A live webcast of the event will be available at http://register.webcastgroup.com/L4/?wid=05682410667. A live webcast of the event will also be available in the Investors section of the company's website at http://investor.ignyta.com, and will be archived and available at that site for 14 days.